FENNEC PHARMACEUTICALS INC.·4

May 1, 5:00 PM ET

Raykov Rosty 4

4 · FENNEC PHARMACEUTICALS INC. · Filed May 1, 2026

Research Summary

AI-generated summary of this filing

Updated

Fennec (FENC) Director Raykov Rosty Exercises Options, Sells Shares

What Happened

  • Director Raykov Rosty exercised stock options and completed a related share sale. On 2026-05-01 he exercised 15,598 options at $2.45 per share (cost = $38,215). That same day he sold 10,781 shares in the open market at $6.47 per share, receiving $69,753. Additionally, 2,778 restricted shares awarded 5/16/2024 were released to him on 2026-04-30 (no cash paid).

Key Details

  • Transaction dates and prices:
    • 2026-04-30: 2,778 shares released from restriction (F1) — acquired at $0.00.
    • 2026-05-01: Exercised 15,598 options at $2.45/share (Acquired) — $38,215 (F2, F4).
    • 2026-05-01: Sold 10,781 shares in open market at $6.47/share — $69,753 (F3).
    • Filing accession: 0001468316-26-000013; report filed 2026-05-01 (timely).
  • Shares owned after the transactions: not specified in the provided transaction details.
  • Notable footnotes:
    • F1: release of restricted shares awarded 5/16/2024.
    • F2/F4: exercise occurred pursuant to a 10b5-1 plan adopted 9/19/2025.
    • F3: the open-market sale was to satisfy tax obligations from the option exercise (per the 10b5-1 plan).
  • Timeliness: Report covers transactions on 4/30 and 5/01 and was filed on 2026-05-01 — appears timely.

Context

  • This was an option exercise with immediate share disposition to cover taxes (a common, routine cashless outcome) rather than a standalone buy indicating new bullish conviction. M = option exercise/conversion; S = sale. The exercise required outlay ($2.45/share); some shares were sold under the 10b5-1 plan to satisfy tax withholding.

Insider Transaction Report

Form 4
Period: 2026-04-30
Transactions
  • Exercise/Conversion

    Common shares

    [F1]
    2026-04-30+2,778116,634 total
  • Exercise/Conversion

    Common shares

    [F2]
    2026-05-01$2.45/sh+15,598$38,215132,232 total
  • Sale

    Common shares

    [F3]
    2026-05-01$6.47/sh10,781$69,753121,451 total
  • Exercise/Conversion

    Stock Options

    [F4]
    2026-05-01$2.45/sh15,598$38,2151,571,792 total
    Exercise: $2.45From: 2016-07-05Exp: 2026-07-05options (15,598 underlying)
Footnotes (4)
  • [F1]Represents shares released from restriction from shares awarded 5/16/2024.
  • [F2]Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025.
  • [F3]Shares sold to satisfy tax obligation on option exercise pursuant to a 10b5-1 plan adopted on September 19, 2025.
  • [F4]Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025.
Signature
/s/ Rosty Raykov|2026-05-01

Documents

1 file
  • 4
    form4-05012026_090522.xmlPrimary